Adrenoleukodystrophy (ALD) - Epidemiology Forecast to 2030
- April 2020 •
- 83 pages •
- Report ID: 5875508 •
- Format: PDF
‘Adrenoleukodystrophy (ALD) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Adrenoleukodystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Adrenoleukodystrophy (ALD) Understanding
Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland. The accumulation of VLCFAs leads to the deterioration of the myelin sheath, and without the sheath, neurons cannot conduct action potentials, this leads to the development of seizures and hyperactivity. There are three basic forms of ALD: neonatal, childhood, and adult-onset. The childhood ALD is the classical and the most severe form leading to total disability or death. It affects only boys because the genetic defect is sex-linked (carried on the X-chromosome). The adult-onset, called AMN is mild, progresses slowly, and usually appears in people aged 21–35 years.
Adrenoleukodystrophy (ALD) Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Adrenoleukodystrophy in the 7MM, Gender-specific Prevalence of Adrenoleukodystrophy in the 7MM, Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the 7MM, and Type-specific Diagnosed Prevalence of ALD in Males in the 7MM. The epidemiology section covers the 7MM countries, the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from the year 2017 to 2030.
Adrenoleukodystrophy (ALD) Detailed Epidemiology Segmentation
As per the analysis, in 2017, the total prevalent population of Adrenoleukodystrophy in the 7MM was 55,242. The analysis also shows that a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries during the study period (2017–2030).
Based on the type of ALD, it was also assessed that majority of the patients suffer from Cerebral ALD (CALD), with 458 cases observed in the US, in 2017, while Adrenomyeloneuropathy (AMN) and Addison Disease account for nearly 305, and 124 cases of the total diagnosed male symptomatic ALD population. Out of the total diagnosed male cases, CALD includes 1,173 cases, which is further divided based on age, i.e., Childhood CALD (904 cases), Adolescent CALD (171 cases), and Adult CALD (98 cases) in 2017 in the US.
Among the European five countries, Germany had the highest diagnosed prevalent population of ALD with 1,699 cases, followed by France and the United Kingdom. On the other hand, Spain had the lowest diagnosed prevalent population of 1,041 in 2017. Japan had 2,155 diagnosed prevalent cases for ALD in 2017.
Scope of the Report
• The report covers the descriptive overview of Adrenoleukodystrophy, explaining its clinical aspects, symptoms, causes, inheritance pattern, pathophysiology, and diagnosis.
• The report provides insight into the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Adrenoleukodystrophy.
• The report helps to recognize the growth opportunities in the 7MM countries for the patient population.
• The report provides the segmentation of the disease epidemiology by Total Prevalent Population of Adrenoleukodystrophy in the 7MM, Gender-specific Prevalence of Adrenoleukodystrophy in the 7MM, Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the 7MM, and Type-specific Diagnosed Prevalence of ALD in Males in the 7MM.
• 11-Year Forecast of Adrenoleukodystrophy epidemiology
• 7MM Coverage
• Total Prevalent Cases of Adrenoleukodystrophy
• Prevalent Cases according to segmentation: Gender-specific prevalence
• Diagnosed cases of Adrenoleukodystrophy according to segmentation: Gender-specific diagnosed prevalence and type-specific diagnosed prevalence of ALD in male
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
• What will be the growth opportunities in the 7MM concerning the patient population of Adrenoleukodystrophy?
• What are the key findings of the Adrenoleukodystrophy epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of Adrenoleukodystrophy across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the forecast period (2017–2030)?
Reasons to buy
The Adrenoleukodystrophy report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Adrenoleukodystrophy market.
• Quantify patient populations in the 7MM Adrenoleukodystrophy market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Adrenoleukodystrophy therapeutics in each of the markets covered.
• Understand the magnitude of the Adrenoleukodystrophy population by its severity.
• The Adrenoleukodystrophy epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Adrenoleukodystrophy Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources.
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017–2030